Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about IMDX, unsubscribe in one click. Privacy
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| adjuvanted trivalent influenza vaccine | Influenza | Phase 4 · NCT02882100 | Completed |
| Baloxavir | Influenza | Phase 4 · NCT05012189 | Unknown |
| Brimonidine Tartrate Ophthalmic 0.025% | Glaucoma | Phase 4 · NCT07209410 | Recruiting |
| Oseltamivir | Influenza | Phase 4 · NCT05012189 | Unknown |
| Trivalent Influenza Vaccine | Influenza | Phase 4 · NCT03965195 | Unknown |
| Standard Dose Quadrivalent Influenza Vaccine | Influenza | Phase 4 · NCT03965195 | Unknown |
| Influenza | Influenza | N/A · NCT03599739 | Completed |
Also used in these trials (approved or third-party drugs, not IMDX's own candidates): Adjuvant.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
IMDX holds $11M in cash and short-term investments (as of Sep 30, 2026) and burns about $7.9M/quarter from operations, an estimated runway of 4.2 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure: 62 · High
The mitigating effect of our plans, however, is only considered if both (1) it is probable that the plans will be effectively implemented within one year after the date that such financial statements are issued, and (2) it is probable that the plans, when implemented, will mitigate the relevant conditions or events…10-Q, Nov 2026
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when IMDX files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| Neal C. Bradsher | Institution (13G, 5%+) | 12,835,134 | 39.18% | 2026-04-23 |
| BROADWOOD PARTNERS, L.P. 10% owner · +150,093 options |
Insider | 12,685,041 | 38.72% | 2026-04-23 |
| Patrick W Smith 10% owner |
Insider | 3,258,485 | 9.95% | 2025-02-07 |
| Andrea S. James Chief Financial Officer · +833,112 options |
Insider | 206,060 | 0.63% | 2026-03-26 |
| Andrew Arno Director · +30,000 options |
Insider | 164,589 | 0.50% | 2026-07-01 |
| Andrew J. Last Director · +30,000 options |
Insider | 58,752 | 0.18% | 2026-07-01 |
| Lou Silverman Director · +30,000 options |
Insider | 55,807 | 0.17% | 2026-07-01 |
| Josh Riggs CEO and President, Director · +730,188 options |
Insider | 38,365 | 0.12% | 2026-03-26 |
| James Yang Liu VP ACCT, Cntlr, Treasurer, PAO · +59,445 options |
Insider | 3,711 | 0.01% | 2026-03-26 |
Share count 32,757,434 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for IMDX and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →